Clinical Trial Update: A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and tolerability of REGN88 (SAR153191) given in multiple doses to rheumatoid arthritis patients. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• REGN88 (SAR153191) (SAR153191)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED